0

Intrexon Partners with Merck Serono on CAR-T Development Deal

Shares of Intrexon Corp (NYSE:XON) soared as much as 8% yesterday after the company had announced that it had formed a collaboration deal with Merck Serono – a German biotechnology company with no relationship to Merck (NYSE:MRK). Intrexon had partnered… Continue Reading

0

RXi Pharmaceuticals Provides Positive Update On Phase 2a Trials And Collaborations

On March 23, 2015 RXi Pharmaceuticals (NASDAQ:RXII) first announced preliminary findings from its phase 2a keloid trial study known as RXI-109-1401. This trial is evaluating  the ability to reduce patients’ recurrence of keloids following keloidectomy. This phase 2a trial is ongoing… Continue Reading

0

Esperion Therapeutics Announces Positive Phase 2b Results In Patients with Hypercholesterolemia

Shares of Esperion Therapeutics (ESPR) are up about 22% after the company reported positive phase 2b results in Hypercholesterolemia. Esperion is using its own drug ECT-1002 which is given to patients in conjunction with these patients taking current Statin therapy.… Continue Reading

0

Acadia Pharmaceuticals Tanks After CEO Retires, and Application To FDA For Parkinson’s Drug Approval Is Delayed

Shares of Acadia Pharmaceuticals (ACAD) tanked about 28% in after hours trading today after the company reported that the CEO will retire and that the New Drug Application — NDA for the company’s Parkinson’s Drug will be delayed. For starters… Continue Reading

0

Orexigen Shares Retreat After Comment From The FDA About Safety Data For Contrave

A few days ago we wrote an article on Orexigen Therapeutics (OREX) about news that the company had achieved positive safety results in a study in addition to slightly improving patients’ cardiovascluar health. Shares of Orexigen had soared big on… Continue Reading

0

Shares Of Orexigen Soar 54% After It announces Improved Safety Results For Weight-loss Drug

Shares of Orexigen Therapeuetics (OREX) are up about 54% after the company reported that its Weight-loss Drug Contrave did not only achieve excellent safety results but also saw improvements in other areas. Such other improvements are that when patients took… Continue Reading

0

Celldex Receives Breakthrough Status For Brain Cancer Drug Rindopepimut

Shares of Celldex Therapeutics (CLDX) were up as much as 16% after the company had announced that it had received breakthrough therapy designation for its cancer drug Rindopepimut. Rindopepimut is a drug that is used to treat patients with Glioblastoma… Continue Reading

0

OncoSec Medical and Heat Biologics Collaborate On Immunotherapy Platforms

OncoSec Medical (ONCS) and Heat Biologics (HBTX) both announced today that they will collaborate on clinical trials that will evaluate each company’s platform in a combination study. Both these biotechnology companies utilize a form of technology that uses immunotherapy platforms.… Continue Reading

0

Shares of Oncolytics Surge 36% After The Company Announced Orphan Drug Status For Its Pancreatic Cancer Drug

Shares of Oncolytics Biotech (ONCY) surged 36% after the company had announced that the FDA has granted Orphan Drug Status for its pancreatic cancer drug REYOLYSIN. Oncolytics is a biotechnology company that focuses on using an environmental virus  to combat… Continue Reading

0

Regulus Therapeutics Announces Final Phase 1 Results For Hepatitis C Study Using RG-101

On February 9th, 2015 Shares of Regulus Therapeutics (RGLS) were down 7% despite reporting good final results from the phase 1 study treating patients with Hepatitis C using their injection drug RG-101. Regulus Therapeutics is a biotechnology company focused on… Continue Reading